To confirm the generalizability of this long-term transcriptional response, we developed and profiled two additional models of evolved resistance to dual-mechanism ERK inhibition in KRAS-mutant lung and colon cancer cells. This evidence concerns the gene KRAS and malignant colon neoplasm.